---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-101531"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2026-08-26T20:30:04+00:00"
generated_at: "2026-08-26T20:31:35.034933+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Phibro Animal Health reports record FY2026 results, raises FY2027 guidance

## Summary
- Q4 net sales $396.7M (+5% YoY); diluted EPS $0.53 (+26%); adjusted EPS $0.85 (+35%).
- FY2026 net sales $1,518.1M (+17%); net income $99.7M; adjusted EBITDA $255.0M (+39%).
- FY2027 guidance: net sales $1.55-1.60B, adjusted EBITDA $258-268M, adjusted net income $140-147M.
- Plans to close Chicago Heights manufacturing facility; production ceases summer 2027, ~100 employees affected.
- Regulatory uncertainty on virginiamycin in Brazil; guidance assumes minimal sales, potential upside if approved.

## SEC filing metadata
- accession: 0001104659-26-101531
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2026-08-26T20:30:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000110465926101531/0001104659-26-101531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000110465926101531/pahc-20260826x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-101531
- JSON: https://secwatch.observer/filing/0001104659-26-101531.json
- Plain text: https://secwatch.observer/filing/0001104659-26-101531.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.